Page 25 - SaxoCell Annual Report22/23
P. 25
CAR- Allo-CAR-Treg
T
AlloCARTreg is developing a universal immunosuppressive cell product for the treatment of
autoimmune and inflammatory diseases through innovative site-specific adapter CAR
technologies.
Project lead: Martin Bornhäuser & Anke Fuchs
Partner: Helmholtz Center Dresden Rossendorf, Technical University Dresden
The projects bundles expertise with clinical scale fully automated polyclonal Treg manufacturing
using the CliniMACS Prodigy (Fig 1A; Fuchs), Treg cell therapy for cGvHD (Bornhäuser), state-of-
the-art universal adaptor RevCAR technology (Fig. 1B; Feldmann) and pioneering genetic
engineering methodology (Buchholz). The project involves comprehensive investigation into the
phenotypic and functional characterization of regulatory T cells (Treg) derived from apheresis and
cord blood as starting population for next generation site specific Treg cell therapy.
It includes the development of improved GMP Treg isolation to reach high purity, optimization of
Treg expansion and integration of CAR transduction into the automated manufacturing process
(Fig. 1C). Furthermore, enhanced specificity and persistence of allogeneic Treg will be realized by
smart genetic engineering towards an off-the-shelf cell product.
Overall, our results to date provide a promising foundation for our vision of allogenic off-the-shelf
immunosuppressive cell therapy with switchable site-targeting that holds the potential to advance
clinical practice in the fi eld autoimmunity and severe inflammation.
20
